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Abstract  
The present study was designed to investigate lectins in sera of patients with kidney tumors, in addition to non tumoral 
kidney disease patients. Fifty five patients of malignant kidney tumors were enrolled in addition to 23 patients of benign 
kidney tumors, and 18 patients of non tumoral kidney diseases used as control groups, in addition to 46 healthy individuals 
were also investigated. The age of patients and healthy individuals were 10-90 years. The measurement of total serum 
proteins revealed significant (p < 0.001) decrease in patients of malignant tumors when compared with those of benign, 
non tumoral diseases, and healthy individuals. The conditions of the hemagglutination assay of serum lectin activity were 
optimized. They were Tris buffer of 20 mM and pH 7.4, 60 mM CaCl2, 800 µg of defatted serum, 30 ˚C for serum samples, 
60 minutes for serum samples, and human blood of group A
+
 suspension with 1.4 optical density. The measurement of the 
specific hemagglutination activity of lectins demonstrated significant (p < 0.001) elevation in patients of malignant tumors 
when compared with those of other patients and healthy individuals. Lectin activity was pointed out to be significantly (r = 
0.767 at p < 0.0005) positively correlated with stage of malignancies. The cutoff value of the specific hemagglutination 
activity was found to equal 6 SHU for discriminatory malignant kidney tumors. Serum lectins activity were indicated to be 
inhibited by galactose, mannose, lactose, and N-acetyl galactosamine. Purification of lectin from sera of patients with 
malignant kidney tumors by affinity chromatography with the use of silver stain revealed N-Acetyl Galactosamine Binding 
Lectin (GalNAcBL). The purified folds and the yield was 178 with 32.4%. The polyacrylamide gel electrophoresis (PAGE) 
of purified lectin demonstrated one band consisted lectin activity. The approximate molecular weight of GalNAcBL was 
determined and found to be 63.83. Purified lectin was characterized through the assessment of the capability to 
agglutinate RBCs, inhibition by EDTA, pH dependency, thermal dependent, and carbohydrate contents. GalNAcBL were 
observed to be calcium dependence lectins (C-type). These results suggest that the diagnosis of the specific 
hemagglutination activity of lectin is promising biomarker for discrimination of malignant kidney tumor patients and the 
purified lectin could be introduced in the field of biomarkers.  
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Introduction 
Lectins are ubiquitous proteins or glycoproteins that are present in all eukaryotic cells [1-6], and many bacterial species [7, 
8], as well as in some viruses [9, 10]. They are capable to bind mono- and oligosaccharides with high affinity [11, 12], and 
usually agglutinate cells or precipitate polysaccharides and glycoconjugates specifically and reversibly [13, 11]. The 
binding involves hydrophobic interactions as well as hydrogen bonds [14]. Lectin specificity for individual sugars or groups 
of sugars makes them powerful tools for detecting changes in the carbohydrate structure of the glycoproteins [15, 16]. 
Several lectins are investigated for their use in cancer research and therapy. Preliminary findings suggest that some 
lectins can detect alterations of malignant cells as well as reduce the cancer cell tumorigenicity and thus may be helpful for 
prognosis of the immune status of the patients [17]. 
Glycoproteins are built up in a sequential step-by-step process in the Golgi apparatus, starting with the addition of N-acetyl 
galactosamine to serine or threonine residues. Subsequently, elongation of O-linked sugars is achieved by transfer of 
additional sugar residues to the already glycosylated protein [18]. These reactions are catalyzed by different 
glycosyltransferases whose specificities, sequential action, relative activity levels, and intracellular localization determine a 
cell-specific O-glycosylation profile. The initial key step in the regulation of O-glycosylation is the transfer of N-acetyl 
galactosamine from UDP- N-acetyl galactosamine to Ser or Thr residues on an acceptor polypeptide. This reaction is 
catalyzed by a family of UDP- N-acetyl galactosamine polypeptide N-acetylgalactosaminyl transferases (ppGalNAc-Ts). 
One mechanism for glycoprotein glycosylation changes in cancer cells could be a differential expression of ppGalNAc-Ts. 
Functional profiles of each component of the family have been characterized showing that these enzymes not only have 
different substrate specificities but also specific tissue-expression patterns [19-21]. Several studies [20, 22-28], attributed 
malignancy to the stimulation of ppGalNAc-T2 or ppGalNAc-T3 in malignant tumor cells, in which different expression 
patterns of these enzyme have been described. Present study designed to investigate the kidney cancer effect in 
activation of glycosylation reaction through purification and evaluate N-acetyl galactosamine binding lectin as a product to 
stimulation of enzymes  of this pathway.  
 
Subjects, Materials, and Methods 
Patient and Control Individuals: The present study involved 96 patients (55 cases with malignant kidney tumors, 23 
cases with benign kidney tumors, and 18 cases with non tumoral kidney diseases) with the age range 10-80 years, in 
addition to 46 healthy individuals, at the same age range. 
Isolation of Crude Lectins from Serum Specimens: Ten milliliters of venous blood samples were collected from 
patients and the control groups. Samples were allowed to clot at room temperature, centrifuged at 3000 xg for 5 minutes, 
and then sera were collected and stored at –15˚C. For isolation of serum crude lectins, 1 volume of serum was mixed with 
2.5 volumes of petroleum ether for defatting. The mixtures were shacked strongly, then, centrifuged at 3000 xg for 5 
minutes. The organic phase was neglected and defatted serum was stored at –15˚C to be used for determination of the 
hemagglutination activity. 
Preparation of Standard Ttrypsinized Erythrocyte Suspension for Hemagglutination Test: Human blood 
group O
+
 erythrocytes were collected from the local blood bank in Al-Sadder Teaching Hospital in Najaf in Iraq. Blood was 
centrifuged at 3000 xg for 5 minutes, the sera were discarded. The erythrocytes were washed with saline solution (5 ml 
saline: 1 ml packed erythrocytes),then were suspended in phosphate buffer saline solution (pH 7.4), and diluted with the 
same buffer to give an absorbance of 2 ml at 620 nm. One part of trypsin solution (1%) was added to 10 parts of the final 
erythrocytes suspension. The mixture was incubated at 37˚C for 1 hour, and then centrifuged at 5000 xg for 5 minutes. 
The trypsinized erythrocytes mixture was washed 3 – 5 times with saline solution to remove trypsin traces. Saline solution 
was added, until the absorbance of the erythrocyte suspension was 1.4 at 620 nm. 
Protein Determination: Total proteins in the studied samples were estimated using Bradford method [29],and bovine 
serum albumin was used as a standard protein.    
Determination of Hemagglutination Activity of Crude Serum Lectins of Patient and Control Groups: To 
determine the hemagglutination activity in serum Lis and Sharon [30] method was used, with essential modifications. The 
procedure involved three tubes, test (T), blank (B), and control (C). A set of control tubes (2 – 4) were used in each 
experiment and the assay was carried out as in the following: 
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Components  Test Blank Control 
1) Diluted serum (1:20) with Tris-HCl buffer (20 Mm, pH 8)  
2) Trypsinized erythrocyte suspension. 
3) Saline solution. 
4) Calcium chloride solution (60 mM). 
1 ml 
2 ml 
- 
1 ml 
1 ml 
- 
2 ml 
1 ml 
- 
2 ml 
1ml 
1 ml 
T, B, and C tubes were placed in exactly vertical position at 37˚C for 75 min. 
Cells were separated after centrifugation at 3000 xg for 3 minutes, then  re-suspended in the above 
mentioned buffer by gentle shaking, and allowed to stand for another 75 minutes at 37˚C. 
The absorbance of 2 ml of the upper mixtures was measured at 620 nm. 
 
The reduction of optical density (ROD) in the test tube (in crude sera determination) was measured from the following 
equation: 
100
C
A
BTAC
A
   ROD% 

  
Where: 
C
A : Optical density of cell suspension in the control tube. 
BT
A

: Optical density of cell suspension in the test tube – Optical density of cell suspension in the blank tube. 
Purification of GalNAcBL: Affinity chromatography technique was applied for the purification of GalNAcBL from 
patients with malignant kidney tumors. Preparation of the affinity chromatography column was carried out according to the 
instructions of Hermanson [31], and Amersham handbook [Amersham Pharmacia Biotech]. 
Determination of Carbohydrate Content in the Purified GalNAcBL: Dubois method [32] was followed for 
determination of carbohydrate amount in the purified GalNAcBL. Where glucose was used as a standard sugar.  
Results and Discussion 
Levels Of The Serum Specific Hemagglutination Activity In Patients and Control Groups: The optimized 
conditions of the hemagglutination protocol were used for estimation of individual serum lectin activity in the studied 
groups. It was expressed as specific hemagglutination activity unit (SHU). Figure 1 demonstrates that 52 patients out of 
the 55 studied patients of malignant kidney tumors have a hemagglutination activity higher than 6 SHU, while those of non 
tumoral kidney diseases and healthy individuals (except one sample in each group) have less than 6 SHU. Also those of 
benign kidney tumors were found to have specific activity less than 6 SHU. These results suggest the possibility of using 6 
SHU as a cutoff value for the specific hemagglutination activity. A result showed the possibility of using this parameter as 
a biomarker for discriminating of patients with malignant kidney tumors among those with benign, non tumoral kidney 
diseases, and healthy individuals.  
 
Fig 1: Distribution of the Serum Hemagglutination Activity in Patients of Malignant Kidney Tumors (K1), 
Benign Kidney Tumors (K2), Non Tumoral Kidney Diseases (K3), and Healthy Individuals (H). The symbol – - 
– - refer to the cutoff of malignant kidney tumors value 
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The evaluation of the specific hemagglutination activity in the various groups revealed a significant increase (p < 0.001) in 
patients of malignant kidney tumors when compared with those of benign tumors, non tumoral kidney diseases, and 
healthy individuals. However, non significant variations were obtained when other groups were compared together (Table 
1). The sensitivity and specificity of serum lectin activity in detection of malignant kidney tumors were 94.54 % and 95.65 
% respectively.  
Table 1: Serum Specific Hemagglutination Activity Levels in Patients of Malignant Kidney (K1) and Benign 
Kidney (K2) Tumors, Non Tumoral Kidney Diseases (K3), and Healthy Individuals (HK1 and HK2) 
 
In the present study, the hemagglutination activity levels in 21 patients with malignant kidney tumors were followed up for 
72 hours after surgical operation, of the removal of the tumor. the result showed presence of a decrease in their serum 
hemagglutination activities after the removal of the tumors (data not shown). 
 
Implication of Stages of Malignancy in Serum and Tissue Specific Hemagglutination Activity: In order 
to verify the changes of the hemagglutination activity with the advancing of malignancy, the patients were subdivided 
according to the stage of the diseases into stage I, II, III, and IV. From the statistical analysis of the malignant kidney 
tumors of different stages, a positive correlation was observed between the serum specific hemagglutination activity & the 
malignant tumor progression (r = 0.767 at p < 0.0005) (Figure 2).  
 
Fig 2: Correlation of Serum Hemagglutination Activity with Stages of Malignant Kidney Tumors 
The mean levels of specific hemagglutination activity in patients of the four stages of malignant kidney tumors are 
illustrated in Table 2. Significant elevations (p < 0.001) of the specific hemagglutination activity were observed when the 
data of each two stages (except III and IV) were compared. 
 
y = 5.5009x
R
2
 = 0.5883
0
7
14
21
28
35
0 1 2 3 4
The Tumor Stage
S
e
ru
m
 S
.H
.U
.
 
Groups 
 
Age (year) 
Mean ± S.D. 
Range 
SHU 
Mean ± S.D. 
 
Range 
 
p 
K1 
(55) 
54.93 ± 12.50 
32 – 80 
14.99 ± 6.21 4.79 – 29.08 0.000** for K1 vs K2 
 
0.000** for K1 vs K3 
 
0.309 for K2  vs K3 
 
0.000** for K1 vsHK1 
 
0.491 for K2 vs HK2 
 
0.724 for K3 vs HK2 
K2 
(23) 
45.04 ± 15.33 
10 – 66 
3.04  ± 1.31 1.17 – 6.49 
K3 
(18) 
42.39  ± 16.60 
12 – 68 
4.44  ± 4.27 0.99 – 20.70 
HK1 
(32) 
47.38 ± 10.92 
32 – 80 
4.27 ± 1.87 1.09 – 9.09 
HK2 
(43) 
39.77 ± 13.77 
10 – 66 
3.94 ± 1.71 1.09 – 9.09 
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Table 2: The Differences in Serum Specific Hemagglutination Activity of Malignant Kidney Tumor Patients 
According to the Stage of the Disease. 
 
Subjects 
Age (year) 
 Mean± S.D. 
Range  
SHU 
Mean± S.D. 
 
Range 
 
p 
Stage І 
(14) 
49.07 ± 11.94 
32 – 74 
8.03 ± 2.40 4.79 – 12.80 
 
 
 
0.000** For (1, 2, 3, 4, and 5) 
 
0.011 for (6) 
Stage П 
(12) 
55.67 ± 13.85 
34 – 79 
12.40 ± 1.21 
 
10.37 – 14.42 
Stage Ш 
(11) 
53.73 ± 9.71 
43 – 75 
17.58 ± 2.73 
 
13.87 – 23.47 
Stage ΙV 
(18) 
59.72 ± 12.40 
41 – 80 
20.55 ± 5.57 
 
7.97 – 29.08 
1) Stage I vs. Stage II  
2) Stage I vs. Stage III        
3) Stage I vs. Stage IV                      
4) Stage II vs. Stage III 
5) Stage II vs. Stage IV 
6) Stage III vs. Stage IV  
 
Gender Involvement in Kidney Lectins Hemagglutination Activity Changes: The effect of gender on the 
kidney specific hemagglutination activity levels in patients of cancerous tumors, benign tumors, and non tumoral kidney 
subgroups was evaluated. Student's t-test failed to exhibit significant changes among male and female patients (Table 
3). 
 
Table 3: Gender Differences of Serum Specific Hemagglutination Activity in Tumoral and non Tumoral Kidney 
Disease Patients and Healthy Individuals. 
Type 
 
Gender 
 
Age (year) 
Mean ± S.D. 
Range  
SHU 
Mean ± S.D. 
Range p 
 
K1 
(55) 
M 
(36) 
57.31 ± 13.69 
32 – 80 
15.48 ± 6.94 4.79 – 29.08  
 
0.259 F 
(19) 
50.79 ± 9.19 
37 – 65 
14.08 ± 4.55 7.97 – 21.69 
 
K2 
(23) 
M 
(14) 
43.93± 16.73 
10 – 66 
2.40 ± 0.77 1.17 – 3.59  
 
0.377 F 
(9) 
47.44 ± 12.28 
25 – 62 
4.04± 1.38 2.45 – 6.49 
 
K3 
(18) 
M 
11)) 
47.36 ± 11.33 
27 – 62 
3.95 ± 1.23 2.05 – 6.00  
 
0.550 F 
(7) 
34.57 ± 21.22 
12 – 68 
5.21 ± 6.92 0.99– 20.70 
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K1:Malignant Kidney Tumor Patient group, K2: Benign Kidney Tumor Patient group, K3: Non Tumoral Kidney 
Patients, and H: total healthy individuals. M: Male, F: Female. The mean difference is significant at 0.001 level  
 
Previously, the source of increased serum lectins in cancer patient was reported to be  unclear [33], but these increases 
may explain through the malignant tumors are the sources of lectin present in the sera  of the malignant patients. 
Increased levels of lectins in malignant tumor specimens may be due to: (1) during malignancy, an increased expression 
of oncogene proteins due to chromosomal translocation, amplification, or mutation that is considered one of the main 
alterations in the cancer cells. Lectin may be one of these proteins. (2) In malignant tumor cells, the loss of tumor 
suppressor gene protein products due to deletion or mutation, may lead to increase the oncogene proteins, where lectin 
may be among them. (3) Genetic imprinting errors and genetic instability leading to progressive loss of regulated cell 
proliferation, increased invasiveness, and increased metastatic potential. Expression of lectins is completely controlled by 
the machinery system of protein synthesis. Therefore, it is prone for alteration during malignant transformation [4]. (4) The 
elevation in several carbohydrates concentrations in malignant cells and the aberrant glycosylation of glycoproteins [16] 
can be considered one of the causes for lectin production.  
In the present study, removal of the tumors, decreased serum hemagglutination activity, thus tumor tissues are most likely 
to produce and secrete lectins in sera. The agglutination test of cancerous tissues showed that lectin was found not only 
on malignant cells but also in macrophages and stromal cells (mainly fibroblasts) near cancer focus, and the stromal cells 
immediately adjacent to cancer nests was found to have higher levels of the hemagglutination activity in comparison to 
cells far from the nests. These results suggest that circulating lectins are generated not only by tumor cells but also from 
peritumoral inflammatory cells and stromal cells. 
 
Purification of Serum Human GalNAcBL: Hydrophobic Affinity Chromatography was used for isolation and 
purification of GalNAcBL from sera of patients with malignant kidney tumors. The purification protocol was carried out by 
using sepharose 6B column activated with bis-oxirane (1, 4 – Butanediol diglycidyl ether) (C10H18O4). The chromatogram 
of the purified GalNAcBL was demonstrated in Figure 3. 
 
Fig 3: Affinity Chromatogram of Malignant GalNAcBL using Sepharose 6B // N-Acetyl Galactosamine Column 
(1.6×1.3( at Flow Rate 30ml / hour. The volume of each fraction was 1 ml. Tris Buffer checked 20mM and 7.4 
pH, contained 60 mM CaCl2 was used as a Washing Solution. The Elution step was carried out using a Tris 
Buffer (20 mM, pH 7.4) contained 10 mM N-Acetyl Galactosamine and 5mM of EDTA. 
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H 
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M 
(21) 
44.24 ± 9.57 
10 -81 
4.69 ± 2.08 1.09– 9.09  
 
0.432 F 
(25) 
44.88 ± 17.10 
11– 87 
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The purification folds and the yield of GalNAcBL from malignant kidney tumors were 178 with 32.4. 
Table 4:  Results of the Purification Protocol of Lectins from Sera of Patients with Malignant Kidney Tumors 
Purification 
step 
Total 
volume 
(ml) 
Total protein 
(mg) 
Total activity 
(HU) 
SHU (HA/µg 
of protein) 
Purification 
(fold) 
Yield % 
MKT Serum 3 45 44.325 0.985 1 100 
GalNAcBL 7 0.0821 14.372 175.055 178 32.4 
MKT: Malignant Kidney Tumor Serum; GalNAcBL: N-Acetyl Galactosamine Binding Lectin 
The analysis of PAGE electrophoresis pattern of purified lectins from patients with malignant kidney tumors is shown in 
Figure 4.   
 
Fig 4: Conventional Ppolyacrylamide Gel Electrophoresis (PAGE) 7.5% for Proteins. Tris - glycin buffer (0.075 
M, pH 8.9) used as the electrode buffer. Prelctrophoresis conditions were 50 mA as a constant current for 30 
minutes, with voltage of 15 v/cm, and at 4ºC.  Electrophoresis was carried out for10 minutes at 20mA, then 
the process was continued  for 3.5 hours at 4ºC by using 40 mA as a constant current and voltage of 15 v/cm. 
The gel was stained for protein with silver stain. 
 
The approximate molecular weights of purified GalNAcBL was determined using conventional PAGE. Five standard 
proteins with known molecular weighs (Lysozyme 13.6 kD, Chemotrypsinogene  25 kD, Ovalbumin  47 kD, Bovine Serum 
Albumin  67 kD, Lactate Dehydrogenase  140 kD)were used. The estimated molecular weight of GalNAcBL was 63.83. 
GalNAcBL Activity toward Various Human Blood Groups: To examine the sensitivity of purified GalNAcBL in 
the agglutination reactions, blood of A
+
, B
+
, and O
+
 groups were used as the source of the erythrocyte samples. O
+
 RBCs 
were indicated to exhibit the maximal agglutination, among the evaluated blood groups, while the hemagglutination 
process of purified lectin (GalNAcBL) was failed . This finding could be explained by differences in glycosylation of the 
surface proteins of red blood cells [34]. Several studies tested the effect of blood sources on the hemagglutination process 
of purified lectins from various sources [35-37]; the result of the present study agreed with some and disagreed with the 
others. 
Inhibition of GalNAcBL Activity by EDTA: The hemagglutination process was carried out for the purified GalNAcBL 
using human O
+ 
red blood cells trypsinized suspension in the presence of EDTA. GalNAcBL lost the hemagglutination 
activity, completely, in the presence of 1×10
-5
 M EDTA. This result clearly indicate that Ca
2+
 is crucial for the expression of 
the hemagglutination activity of GalNAcBL, thus; GalNAcBL should be classified as C-type lectin. 
Relevance of GalNAcBL Activity with pH Changes: The effect of pH on the activity of the four purified GalNAcBL 
was investigated. Figure 5 points out that maximal lectin activity was achieved at pH 7.4 regardless to the source of the 
examined GalNAcBL, while the purified lectins were sensitive to acidic (pH 3) and to basic (pH 12) conditions, under which 
the activities were completely lost. 
- 
+ 
Purified 

Crude Top 
Origin  
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Fig 5: Effect of the pH on Purified GalNAcBL Hemagglutination Activity 
Thermal Stability of GalNAcBL Activity:To explore the effect of temperature on the hemagglutination activity of 
purified GalNAcBL, it was incubated at various temperatures (0
°
C, 30
°
C, 40
°
C, 50
°
C, 60
°
C, 80
°
C, and 100
°
C) for 1 hour; 
the mixtures were cooled until room temperature. The hemagglutination activity was carried out at 30
°
C [37]. Thermal 
stability results revealed that purified lectins remained stable below 40ºC for one  hour with no loss of hemagglutination 
activity, while; they loss about 40% of their hemagglutination activity at 50 ºC. Lectin activity disappeared when the 
denaturation was carried out at more than 60 ºC (Figure 6). 
 
Fig 6: Thermal Denaturation of Purified GalNAcBL Hemagglutination Activity 
The influence of temperature on the hemagglutination activity of purified GalNAcBL was also evaluated through the 
incubation of purified GalNAcBL with erythrocyte suspension at 0, 32, 37, 45, 60, and 75˚C. 37˚C seems to be more 
suitable among the examined temperatures for the agglutination process of purified GalNAcBL (Figure 7). 
 
Fig 7: Temperature Effect on the Purified GalNAcBL Hemagglutination Activity 
The Carbohydrate Content in Purified Lectins: Total carbohydrate content was found to be 8.7 % from the 
purified GalNAcBL. 
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